Published in Pharma Investments, Ventures and Law Weekly, August 7th, 2005
The purchase price of $200 million in cash represents the equivalent of 18.6-times 2004 net earnings. The acquisition will accelerate Bausch & Lomb's expansion into the rapidly growing ophthalmic pharmaceuticals market in China.
In addition, Bausch & Lomb has agreed in principle to a future acquisition of an additional 15% interest in CTF held by two other entities, for $54.5...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Investments, Ventures and Law Weekly